Telcon RF Pharmaceutical
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Telcon RF Pharmaceutical is a South Korean health-care company operating in the pharmaceuticals space, listed on KOSDAQ, Korea's technology and small-cap stock exchange.
The filing's table of contents references both pharmaceutical products and research and development activity, suggesting it supplies medicines or related health-care products to patients or health-care providers. The filing does not provide sufficient product-level detail to identify a single dominant product line or structural business fact beyond its pharmaceutical focus.
Summary is AI-generated and may contain errors · figures from DART filings
Telcon RF Pharmaceutical in five facts
What does Telcon RF Pharmaceutical do?
Telcon RF Pharmaceutical is a South Korean health-care company operating in the pharmaceuticals space, listed on KOSDAQ, Korea's technology and small-cap stock exchange.
Where is Telcon RF Pharmaceutical listed and in which sector?
Telcon RF Pharmaceutical (Korean name: 텔콘RF제약) trades under KRX code 200230 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Telcon RF Pharmaceutical?
Its market capitalisation was US$15.4M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Telcon RF Pharmaceutical's latest annual revenue and operating profit?
For fiscal year 2025, Telcon RF Pharmaceutical reported revenue of US$32.6M, operating profit of US$542.4K and a net loss of US$8.6M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 14.0% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on large shareholdings (5% rule) (abbreviated)Oct 12
- Supply contract signed (voluntary)
Telcon RF Pharmaceutical disclosed a supply contract with KT Corp., worth US$1.72M, about 5.34% of its recent annual revenue, running through Sep 2027.
Supply contract · Oct 2 - Material event report (decision to redeem own convertible bonds early)
Telcon RF Pharmaceutical Co., Ltd. decided to redeem US$2M face value of its Tranche No. 23 private convertible bonds before maturity for US$2.08M by mutual agreement with bondholders Sangsangin Savings Bank and Sangsangin Plus Savings Bank, leaving US$4.66M face value outstanding; the bonds will be cancelled after acquisition.
Capital raise · Sep 29 - Change of largest shareholder
Telcon RF Pharmaceutical's largest shareholder changed on July 14, 2026 from Newon Co., Ltd. and two others (1,518,291 shares, 21.23%) to Evercore Investment Holdings Co., Ltd. and two others (3,848,207 shares, 40.58%), following payment for a third-party-allotment rights offering.
Ownership change · Jul 14 - [Amended] Supply contract signed
Telcon RF Pharmaceutical updated a previously disclosed supply contract with Emmaus Life Sciences.Inc., now worth US$35.9M, about 181.15% of its recent annual revenue, running through Jul 2027.
Supply contract · Jul 10 - Material event report (rights offering)
Telcon RF Pharmaceutical disclosed a private placement (third-party allotment) to raise US$3.27M, about 22.8% of its market value.
Capital raise · Jul 6 - Decision to acquire shares/equity in another company
Telcon RF Pharmaceutical disclosed an acquisition of KPM Tech, worth US$14.6M.
M&A · Jul 3 - Trading suspension (share consolidation/split registration)M&A · May 29
- Material event report (decision to redeem own convertible bonds early)Capital raise · May 27
- Material event report (rights offering)
Telcon RF Pharmaceutical disclosed a private placement (third-party allotment) to raise US$2M, about 13.7% of its market value.
Capital raise · Apr 7 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Telcon RF Pharmaceutical reported consolidated results for FY2025: revenue of US$29.1M (+13.99% year on year), operating profit of US$471K (from a loss a year earlier) and a net loss of US$7.89M.
Earnings · Mar 4